UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

November 20, 2020

(Date of Report—date of earliest event reported)

InMed Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in Its Charter)

(604) 669-7207

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.07: Submission of Matters to a Vote of Security Holders

On November 20, 2020, InMed Pharmaceuticals Inc., or the “Corporation”, held its Annual and Special General Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:

Proposal No. 1 – Election of Directors

The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2021 Annual General Meeting:

Proposal No. 2 – Appointment of Independent Registered Public Accounting Firm

The Corporation’s shareholders voted to approve the appointment of KPMG LLP as the independent registered public accounting firm of the Corporation until the next annual shareholders’ meeting or until a successor is named.

Proposal No. 3 – Amendment of Stock Option Plan

The Corporation’s shareholders voted to approve an amendment to the Corporation’s stock option plan in order to (1) update the definition of “Blackout Period” and (2) extend the period after a Blackout Period that an option may be exercised.

Proposal No. 4 – Amendment to Articles

The Corporation’s shareholders voted to approve an amendment to Section 11.3 of the Articles of the Corporation that increases the quorum for any meeting of shareholders to two persons present at the opening of the meeting who are entitled to vote thereat either as shareholders or as proxy holders and holding or representing not less than 33-1/3% of the outstanding common shares entitled to be voted at the meeting.

2

Item 9.01 Exhibits.

(d) Exhibits.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:    November 24, 2020

4